Abstract
Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
| Original language | English |
|---|---|
| Pages (from-to) | 41-51 |
| Number of pages | 11 |
| Journal | Recent Patents on Anti-Infective Drug Discovery |
| Volume | 9 |
| Issue number | 1 |
| Publication status | Published - Jan 1 2014 |
Keywords
- Cobicistat
- Elvitegravir
- Emtricitabine
- Resistance
- Side effects
- TenofovirDF
ASJC Scopus subject areas
- Infectious Diseases
- Pharmacology (medical)
- Drug Discovery
- Medicine(all)